Long
BNO Short Term 48%
(ASX:BNO) Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia, France, and the United States.
Long for 48% if History Repeats
- Break in LONG TERM Downtrend
- Bullish Market Structure
- Respecting Pitchfork
- Identical Fractal Pattern Setup
- CCI Trending UP
- EMA 10/20 Death cross BUT 10 starting to turn again.
- EMA 50/100 Cross (Needs to spread)
- MACD starting to squeeze and anticipating the CROSS
- Seller Volume Exhausted
- Risk/Reward 4.1:1
If buyers come into the market should have no trouble hitting 20% (First TP). Aiming for the 2.618 Fib Extension but wary of the .5 Fib Retracement of the Higher Timeframe at 0.085
These Ideas are NOT 'Financial Advice'!. Scenarios are based off a mixture of TA and Fundamentals current at the time. All IMO GLTAH. Happy Hunting!!!
Long for 48% if History Repeats
- Break in LONG TERM Downtrend
- Bullish Market Structure
- Respecting Pitchfork
- Identical Fractal Pattern Setup
- CCI Trending UP
- EMA 10/20 Death cross BUT 10 starting to turn again.
- EMA 50/100 Cross (Needs to spread)
- MACD starting to squeeze and anticipating the CROSS
- Seller Volume Exhausted
- Risk/Reward 4.1:1
If buyers come into the market should have no trouble hitting 20% (First TP). Aiming for the 2.618 Fib Extension but wary of the .5 Fib Retracement of the Higher Timeframe at 0.085
These Ideas are NOT 'Financial Advice'!. Scenarios are based off a mixture of TA and Fundamentals current at the time. All IMO GLTAH. Happy Hunting!!!
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.